2004•Chinese journal of integrated traditional and Western medicineRequires access
Clinical Study on the Efficacy and Safety of Lamivudine in the Treatment of Chronic Severe Hepatitis B
Peng Hong
Open publisher page 0 citations
Abstract
Objective:To evaluate the efficacy and safety of Lamivudine in the treatment of chronic severe hepatitis due to hepatitis B virus (HBV). Methods:Eighty-six patients with chronic severe hepatitis caused by HBV were randomly allocated into two groups. Control group (n=38) was given conventional therapy;Lamivudine group(n=48) was treated with Lamivudine, 100mg daily on the basis of routine management. The mortality rate and hospital stay duration of two groups were analyzed. Results:The mortality rate of Lamivudine group was 41.7%. The mortality rate of control group was 68.4%. There was significant difference in mortality between the two groups( P 0.05). The mean hospital stay duration of control group was greatly longer than that of Lamivudine group[(114.3±26.2) days vs.(74.6±22.7) days, P 0.05].No remarkable adverse effects of Lamivudine were observed.Conclusions:Lamivudine may be effective and safe in the treatment of chronic severe hepatitis due to exacerbation of chronic hepatitis B.